 |
Doug Macron is the editor of GenomeWeb's Gene Silencing News. He covers research and therapeutic applications of RNAi, miRNA, and other gene-silencing technologies. E-mail Doug Macron or follow his GenomeWeb Twitter account at @Genesilencing. |
Isis Studies Suggest Therapeutic Potential of Single-Stranded RNAi Molecules
September 06, 2012
Isis Studies Suggest Therapeutic Potential of Single-Stranded RNAi Molecules
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Isis Exec Sees Antisense as Third Major Drug Platform, Says More Work to Be Done
April 19, 2012 / Gene Silencing News - Santaris Advances Two Hypercholesterolemia Rx Candidates; One Poised to Enter Clinical Trials in 2010
November 5, 2009 / Gene Silencing News - Alnylam Forms Alliance with Genzyme in ATTR, Adds Another Notch to Partnership Belt
October 25, 2012 / Gene Silencing News - Alnylam, Isis Announce Notice of Allowance for RNAi-Related Patent Application
December 17, 2009 / Gene Silencing News - Regulus Receives Notice of Allowance on miRNA Antagonist Patent Application
August 13, 2009 / Gene Silencing News